Valerylfentanyl

Valerylfentanyl is an opioid analgesic that is an analog of fentanyl and has been sold online as a designer drug. It has been seldom reported on illicit markets and there is little information about it, though it is believed to be less potent than butyrfentanyl but more potent than benzylfentanyl.[1] In one study, it fully substituted for oxycodone and produced antinociception and oxycodone-like discriminative stimulus effects comparable in potency to morphine in mice,[2] but failed to stimulate locomotor activity in mice at doses up to 100 mg/kg.[3]

Valerylfentanyl
Legal status
Legal status
  • CA: Schedule I
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • US: Schedule I
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC24H32N2O
Molar mass364.533 g·mol−1
3D model (JSmol)

Side effects

Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[4] A new wave of fentanyl analogues and associated deaths began in around 2014 in the US, and have continued to grow in prevalence; especially since 2016 these drugs have been responsible for hundreds of overdose deaths every week.[5]

Valerylfentanyl is a Schedule I controlled drug in the USA since 1 February 2018.[6]

See also

References
  1. Prekupec, Matthew P.; Mansky, Peter A.; Baumann, Michael H. (2017). "Misuse of Novel Synthetic Opioids". Journal of Addiction Medicine. 11 (4): 256–265. doi:10.1097/ADM.0000000000000324. PMC 5537029. PMID 28590391.
  2. Walentiny, D. Matthew; Moisa, Léa T.; Beardsley, Patrick M. (15 May 2019). "Oxycodone-like discriminative stimulus effects of fentanyl-related emerging drugs of abuse in mice". Neuropharmacology. 150: 210–216. doi:10.1016/j.neuropharm.2019.02.007. ISSN 0028-3908. PMID 30735691.
  3. Varshneya, Neil B.; Walentiny, D. Matthew; Moisa, Lea T.; Walker, Teneille D.; Akinfiresoye, Luli R.; Beardsley, Patrick M. (1 June 2019). "Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances". Neuropharmacology. 151: 171–179. doi:10.1016/j.neuropharm.2019.03.023. ISSN 0028-3908. PMID 30904478.
  4. Jane Mounteney; Isabelle Giraudon; Gleb Denissov; Paul Griffiths (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe". International Journal of Drug Policy. 26 (7): 626–631. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.
  5. Armenian P, Vo KT, Barr-Walker J, Lynch KL (2017). "Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review". Neuropharmacology. 134: 121–132. doi:10.1016/j.neuropharm.2017.10.016. PMID 29042317.
  6. "Schedules of Controlled Substances: Temporary Placement of Seven Fentanyl-Related Substances in Schedule I". Federal Register. 1 February 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.